A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition ...

In 2021, 529 million people were living with diabetes worldwide, and an estimated 1·31 billion individuals are projected to ...

The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatment. Instead, s ...

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...

Enhanced weight loss effects of NT-0796 and semaglutide in combination ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Use of antibiotics between birth and 2 years of age was associated with a 20% increased risk for childhood obesity.

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.